Optinose Inc (OPTN) - News Archive

Article for The CSI MarketOptinose s Balancing Act: Prescription Growth Amid Financial Struggles and Strategic RestructuringIn the realm of pharmaceuticals and biotechnology, companies oftentimes navigate a precarious b...

Optinose, Inc. Announces 1-for-15 Reverse Stock Split as Part of Strategic Restructuring Ahead of New Trading YearYARDLEY, Pa. In what marks a significant repositioning for the company, Optinose, Inc. (NASDAQ: OPTN) has...

In a notable strategic move, OptiNose, Inc. (NASDAQ: OPTN), a pharmaceutical company dedicated to meeting the needs of patients treated by ear, nose, and throat (ENT) and allergy specialists, announced on October 16, 20...

: Chronic rhinosinusitis (CRS) remains a significant health burden affecting millions globally, often necessitating intricate therapeutic strategies for optimal management. This article discusses the recent findings pub...

In a breakthrough development, the US Food and Drug Administration (FDA) has officially approved XHANCE as the first and only medication indicated for the treatment of Chronic Rhinosinusitis (CRS) without nasal polyps....

Optinose Announces Positive Results of XHANCE Clinical Trial in the Journal of Allergy and Clinical Immunology: In Practice Optinose, a pharmaceutical company specializing in innovative therapies for chronic sinusitis,...